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Abstract: In 2019, more than 200 cases of Chlamydia trachomatis negative/equivocal by the Aptima
Combo 2 assay (AC2, target: 23S rRNA) with slightly elevated relative light units (RLUs), but positive
by the Aptima Chlamydia trachomatis assay (ACT, target: 16S rRNA) have been detected in Finland
To identify the cause of the AC2 CT false-negative specimens, we sequenced parts of the CT 23S
rRNA gene in 40 specimens that were AC2 negative/equivocal but ACT positive. A single nucleotide
polymorphism (SNP; C1515T in the C. trachomatis 23S rRNA gene) was revealed in 39 AC2/ACT
discordant specimens. No decrease in the number of mandatorily notified C. trachomatis cases was
observed nationally in Finland in 2010–2019. When RLUs obtained for AC2 negative specimens were
retrospectively evaluated in 2011–2019, a continuous increase in the proportion of samples with RLUs
10–19 was observed since 2014, and a slight increase in the proportion of samples with RLUs 20–84
in 2017–2019, indicating that the Finnish new variant of C. trachomatis might have been spreading
nationally for several years. This emphasizes that careful surveillance of epidemiology, positivity rate
and test performance are mandatory to detect any changes affecting detection of infections.
Keywords: Chlamydia trachomatis; mutation; nucleic acid amplification test; diagnostics; false negative
1. Introduction
Chlamydia trachomatis is the most common bacterial sexually transmitted infection globally with
more than 127 million new cases among adults estimated in 2016 [1]. In 2017, more than 400,000 C.
trachomatis infections were reported by 26 European countries to the European Centre for Disease
Prevention and Control (ECDC) [2]. Sexually active young people have the highest risk of being
infected with C. trachomatis. The clinical outcome of the infection varies: males most frequently have
urethritis and females cervicitis. However, the vast majority of chlamydial infections, particularly in
females, are asymptomatic [3]. This poses significant challenges for detection.
Laboratory diagnosis of C. trachomatis infection is currently mainly based on nucleic acid
amplification tests (NAATs) due to their superior performance characteristics. NAATs enable very
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sensitive and specific detection of microbial nucleic acid present even in small quantities. No viable
infectious microbes are required, so transport and storage conditions of specimens are less critical. In
addition, less invasively collected samples, including first void urine (FVU) specimens from males
and vaginal swabs from females, are very effective for C. trachomatis NAAT testing which facilitates
self-sampling and screening of asymptomatic infection.
Microbial sequences selected as detection targets for primers and probes in diagnostic NAATs
must be conserved and specific. The genome of C. trachomatis consists of chromosomal DNA and
a multicopy cryptic plasmid. Most of the US FDA-approved NAATs detecting C. trachomatis and
Neisseria gonorrhoeae are widely used in high-resourced settings and include PCR (Abbott RealTime
CT/NG assay, Roche Cobas CT/NG Test, Cepheid GeneXpert Xpert CT/NG, Becton Dickinson Molecular
Diagnostics BD Max CT/GC/TV), strand displacement amplification (SDA; BD ProbeTec Viper) and
transcription mediated amplification (TMA; Hologic Aptima Combo 2 assay (AC2)) technology. These
technologies amplify chlamydial cryptic plasmid DNA, genomic DNA or rRNA, and the Abbott and
Roche NAATs have dual targets for C. trachomatis. In theory, use of a multicopy target increases
sensitivity, and the exploitation of the multicopy cryptic plasmid as well as multicopy ribosomal RNA
as NAAT targets for C. trachomatis results in high sensitivity [4]. Despite all these advantages, use of
NAATs is not without challenges. Microbial, including chlamydial, genomes are not stable, but must
evolve to survive through minor mutations, insertions, deletions, and horizontal gene transfer [5].
The C. trachomatis genome was initially considered to be highly conserved, however, it has now been
shown that recombination in C. trachomatis intracellularly is frequent in vitro [6] and in vivo [7]. When
evolutionary changes take place in the sequence where NAAT primers and/or probe bind, the test
performance can be compromised, and the test can become unreliable and clinically useless [8].
Chlamydial diagnostic NAATs have not been spared from such challenges. In 2006, the number of
mandatorily notified C. trachomatis cases decreased dramatically in the majority of counties in Sweden,
and eventually, the Swedish new variant of C. trachomatis (the Swedish nvCt) was described [9].
The Swedish nvCT contained a 377 bp deletion in the cryptic plasmid DNA, excluding the target
region for the Abbott and Roche C. trachomatis NAATs available at that time. This strain was widely
spread nationally in Sweden [10], but with exception of Norway few cases were detected outside
Sweden [11,12]. Due to the Swedish nvCT, Abbott and Roche developed the dual target NAATs
mentioned above. In February 2019, a few urogenital samples reported negative for C. trachomatis by
the AC2 (target: 23S rRNA) but with slightly elevated detection signal (relative light units, RLUs), and
positive for C. trachomatis by Allplex STI test were detected in Turku, Finland [13]. These samples
tested positive by the Aptima C. trachomatis assay (ACT; target: 16S rRNA) provided by Hologic.
Later, several similar cases of C. trachomatis that were negative/equivocal by AC2 but positive by ACT
were identified in several laboratories using AC2 in Finland. During March–April 2019, 87–100% of
specimens with RLUs 20–84 interpreted by the assay software as negative or equivocal and 20% of
those with RLUs 15–19 interpreted by the assay software as negative were shown to be positive for C.
trachomatis when using a test with alternate target (ACT) [13].
We retrospectively analyzed the C. trachomatis incidence in Finland (2010–2018), and positivity
rates as well as number and proportion of AC2 negative specimens with slightly elevated RLUs (20–84)
from 2016–2018 in three laboratories in Finland and negative specimens from 2011–2019 in Clinical
Microbiology Laboratory of Helsinki University Hospital (HUSLAB). We also sequenced parts of the
23S rRNA gene and determined the C. trachomatis ompA-based genotype in 40 specimens that were
AC2 negative/equivocal but ACT positive.
2. Materials and Methods
2.1. Retrospective Analysis of C. trachomatis Incidence, Positivity Rates and AC2 RLUs
Incidence data of sexually transmitted C. trachomatis infection in 2010–2018 from the Infectious
Diseases Register (NIDR) maintained by National Institute of Health and Welfare (THL, www.thl.fi) was
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used. Furthermore, data was collected on the percentage of specimens positive for C. trachomatis and on
the percentage of negative specimens with RLUs 10–19 and 20–84 in AC2 tests in three major Finnish
laboratories; Clinical Microbiology Laboratory of Turku University Hospital (Tyks, serving hospital
district of Southwest Finland), Clinical Microbiology Laboratory of Helsinki University Hospital
(HUSLAB, serving hospital district of Helsinki and Uusimaa and hospital district of Kymenlaakso),
and United Medix Laboratories Ltd (UML, part of SYNLAB Finland, serving private sector clients and
Finnish Student Health Service organization operating in the whole of Finland).
2.2. Samples
Anonymized samples collected with the Aptima Urine Specimen Collection Kit for Male and
Female Urine Specimens or with the Aptima Kit for Endocervical and Male Urethral Swab Specimens
were available for this study. Samples were sent for CT/NG testing with AC2 run on automated Panther
instruments and the test results were automatically interpreted by the Aptima Assay software [14]. The
cutoffs are RLU 25 for equivocal (RLU ≥ 25– < 100) and 100 for a positive result if only a chlamydial
signal is detected. If both chlamydial and gonococcal signals are present or the chlamydial result is
indeterminate, the cutoff for C. trachomatis equivocal is 85 RLU (RLU ≥ 85– < 250). Samples with
≥250 RLU are positive for C. trachomatis, if both chlamydial and gonococcal signals are present [14].
Samples that were negative in the AC2 test but positive in ACT were further investigated. Six such
specimens from Tyks, 21 from HUSLAB, and 13 from UML were available for this study (the specimens
were collected between January and April 2019, except sample No. 6 that was collected in June
2018). For comparison, five AC2 positive first-void urine samples and 26 C. trachomatis positive
swab specimens collected in Universal Transport media in 2009–2015 for culture were included in the
analysis. The study was approved by the Independent Institutional Review Board of Hospital District
of Helsinki and Uusimaa (12 June 2019; HUSLAB 88§/2019).
2.3. DNA Extraction
Genomic DNA was extracted from all specimens using the Maxwell®16 Viral Total Nucleic Acid
Purification Kit (Promega, Madison WI, USA). Briefly, 300 µL of each specimen was mixed with 300 µL
of lysis buffer supplemented with 30 µL proteinase K and incubated at 56 ◦C for 10 min. DNA was
then extracted from the specimen lysate with the Maxwell 16 instrument and the isolate DNA was
eluted in 50 µL of nuclease free water.
2.4. PCR and Sequencing
Overlapping fragments of the 23S rRNA gene of C. trachomatis were amplified in duplicate with
PCR. The primers used for PCR and sequencing are shown in Table 1. The PCR reactions of 25 µL
contained 12.5 µL Maxima Probe/ROX qPCR Master Mix (2×) (Thermo Scientific, Waltham, MA,
USA), and 200 nM of forward and reverse primers (purchased from Integrated DA technologies).
Amplification was performed on a 7500 Real-Time PCR system (Applied Biosystems, Foster City,
CA, United States). Cycling conditions were 95 ◦C 10 min initial denaturation, followed by 45 cycles
of 95 ◦C/15 s, 62 ◦C/15 s and 72 ◦C/1 min. PCR products were visualized on 1% agarose gel by
electrophoresis. The PCR amplicons were then purified (Illustra ExoProStar 1-Step kit, GE Healthcare
Life Sciences, Buckinghamshire, UK) and the forward and reverse strands of the PCR products were
Sanger sequenced twice in the Institute for Molecular Medicine, Finland. Sequences were compared to
the known C. trachomatis sequences in the NCBI database by BLAST analysis (megablast) and multiple
sequence alignment. Additionally, the previously sequenced Finnish C. trachomatis low-passage
number isolates [15] from AC2 positive patients (the sequencing data deposited in the European
Nucleotide Archive, ENA, http://www.ebi.ac.uk/ena, [7]) were used in sequence comparisons.
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Table 1. The primers used in this study.
Name Sequence Amplicon Size Reference
U23
23SIG
F:
5′-GATGCCTTGGCATTGATAGGGGATGAAGGA-3′
R: 5′-TGGCTCATCATGCAAAAGGCA-3′
604 bp [16]
23S V1
F: 5′-AAGACCGACCTCAACACCTG-3′ 823 bp This study
R: 5′-GCGATGTCGGTTTTATGCTT-3′
23S V2
F: 5′-GGCTTACCAACGGAAATCAA-3′ 741 bp This study
R: 5′-GCGATGTCGGTTTTATGCTT-3′
23S V3
F: 5′-AGCGAAGGAATGACGGAGTA-3′ 656 bp This study
R: 5′-AAGGTTCACGGGGTCTTTTC-3′
23S V4
F: 5′-TGAACCTAAGCCCTGGTGAATGGC-3′ 897 bp This study
R: 5′-CTTGAGGGAGGCTTGGCATT-3′
2.5. Genotyping
The C. trachomatis specimens were genotyped using an earlier developed ompA-based PCR
method [17] with previously described modifications [11].
3. Results
3.1. C. trachomatis Incidence
The incidence based on the mandatory laboratory notifications of C. trachomatis cases in five
hospital districts where AC2 is used, from 2010 to 2018, is presented in Figure 1 (data from NIDR).
The figure shows about 10% decrease in the incidence of notified C. trachomatis cases in the hospital
districts of Southwest Finland (Turku area) and Kymenlaakso in 2018. However, these changes did not
reach statistical significance. No decrease in the incidence of C. trachomatis was observed in 2017–2018
in the hospital districts of Helsinki and Uusimaa, and Päijät-Häme. No decrease in the number of
mandatorily notified C. trachomatis cases was observed nationally in Finland in 2010–2019.
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3.2. Retrospective Analysis of C. trachomatis Positivity Rates
The percentage of AC2 specimens interpreted by the Panther instruments as positive for C.
trachomatis in three laboratories is presented in Figure 2. In 2016–2017, approximately 6%, 5%, and 5%
of AC2 specimens were positive in Tyks, HUSLAB, and UML, respectively. In Tyks, the percentage of
positive samples was exceptionally high in 2017, reflected also as a higher incidence in Figure 1. There
was a small but continuous decrease in the positivity rate in Q2–Q4/2018 in Tyks. In HUSLAB, there
was a continuous slowly decreasing trend in the proportion of positive samples since 2011, but no
major changes during 2016–2018.
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Figure 2. Quarterly proportions of Apti a o bo 2 specimens positive for C. trachomatis in three
diagnostic laboratories in Finland in 2016–2018. total number of specime s included was 287,000
(Clinical Microbiology Labor t y f Helsinki University Hospital (HUSLAB), serving hospital district
of Hel inki and Uusima and hospital istrict of Kymenlaakso) a d 61,000 (Clinical Microbiology
Laboratory of Turku University Hospital (Tyks), serving hospital district of Southwest Finland).
The number of United Medix Laboratories Ltd (UML) samples was not available.
3.3. Retrospective Analysis of RLUs
During March–April 2019, 87–100% of specimens with RLUs 20–84 interpreted by the Panther
system as negative or equivocal were shown to be positive for C. trachomatis when using a test with
alternate target (ACT) [13]. Figure 3 shows the proportions of AC2 samples with RLU 20–84 in the three
laboratories in 2016–2018. In HUSLAB, their proportion started to increase in the first quarter of 2017,
and in the last quarter of 2017, their proportion reached 1.2% of all AC2 samples. The maintenance
history of the Panth r instruments revealed no technical or software issues connected with the increase.
At UML, the proportion of samples with RLU 20–84 increased in a similar fashion, but th percentages
were lower (reaching 0.8% in Q1/2018). In Tyks, the increase i the percentage of samples with
RLUs 20–84 was observed somewhat later, namely in 2018. In Tyks, already in 2016–2017, increased
proportions of specimens with elevated RLU were seen, but this was mainly due to technical issues as
the proportions decreased after Panther service visits.
When proportioned to the samples reported as positive for C. trachomatis, the percentage of
samples negative for C. trachomatis with RLU 20–84 in HUSLAB was 8.6%, in Tyks 5.7% and in UML
7.1%. This may represent the amount of missed C. trachomatis cases, as in 2019, up to 100% of specimens
with RLUs 20–84 interpreted by the assay software as negative or equivocal were shown to be positive
for C. trachomatis when using a test with alternate target (ACT) [13].
Retrospective analysis of 433,873 AC2 negative samples tested in HUSLAB from June 2011 to
February 2019 (Figure 4) indicates that the proportion of specimens with RLUs 10–19 started to increase
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in late 2014 (10%) and reached 40% of negatives in 2018 in that area. This might be due to technical
issues (related to AC2 reagents or Panther instruments) or the appearance and gradual dissemination
of a C. trachomatis variant giving slightly elevated RLUs in the AC2 test.Microorganisms 2019, 7, x FOR PEER REVIEW 6 of 12 
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Figure 4. AC2 negative specimens analyzed in the Helsinki University Hospital Laboratory from June
2011 to February 2019 accordi g to their RLU result. Data for this analysis were available from 434,000
specimens. Black bars represent negative specimens yielding an RLU result between 20 and 85; the
blue bars represent negative specimens yielding an RLU result between 10 and 19; and the light blue
bars represent all other negative specimens (RLU < 10). The red line represents the proportion (%) of
specimens yielding an RLU result between 20 and 85, and the purple line represents the proportion (%)
of specimens yielding an RLU result between 10 and 19.
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3.4. PCR and Sequencing of 23S rRNA Gene
Initially, five primer pairs were used to amplify C. trachomatis sequences coding for 23S rRNA
of 11 specimens (specimens 1–5 and 7–12 in Table 2). All fragments were successfully amplified and
sequenced in six, four fragments in three, and three fragments in two specimens. Sanger sequencing
detected a single nucleotide polymorphism (SNP) at position C1515T in the C. trachomatis 23S rRNA
gene in all AC2 negative but ACT positive samples when compared to the C. trachomatis E/Bour
(HE601870) (Figure 5) sequence. The SNP was verified in both the forward and reverse strands of the
sequenced V2 and V3 PCR products, with high quality values (Q-value > 30 by FinchTV, Geospiza).
This SNP verifies that AC2 negative but ACT positive specimens contained the Finnish new variant
of C. trachomatis (FI-nvCT) [18]. As this was the only mutation detected in the sequenced regions of
the 23S rRNA gene, only primer pair V2 was used to amplify 29 additional AC2 negative/equivocal
and ACT positive specimens, and the five AC2 positive specimens. Twenty-eight of these 29 AC2
negative/ACT positive specimens had the C1515T SNP, whereas one AC2 equivocal specimen (number
16) and the five AC2 positive specimens did not have this mutation. The equivocal specimen yielded
RLU 66 in AC2 and RLU 6948 in ACT. As the specimen was tested with ACT and then included in this
study, the AC2 test could not be repeated.
DNA sequences from 32 Finnish low-passage-number cervical isolates [15], including 12
representing genotype E, from an earlier study [7] were also analyzed. None of these isolates
collected from AC2 positive patients in Finland in 2009–2011 had this SNP. Twenty-six culture-positive
swabs from 2009–2015 collected in Helsinki were also analyzed for the presence of this SNP, and they
all contained a 23S rRNA gene of wild-type.
3.5. Genotyping
All specimens that were AC2 negative but ACT positive contained C. trachomatis genotype E. The
AC2 equivocal specimen (number 16) with wild-type 23S rRNA sequence contained C. trachomatis
genotype G (Table 2).
Table 2. Characteristics of specimens with negative/equivocal * Aptima Combo 2 and positive Aptima
Chlamydia trachomatis results.
Specimen Number,
GenBank Accession
Number
Specimen
Type
Patient’s AC2
RLU
(×1000)
ACT
RLU
(×1000)
Genotype
MOMP
Sequence of Amplicons
Sex Age U23, 23SIG V1 V2 V3 V4
1
MN006991 FVU M 32 26 6405 E WT WT C1515T C1515T WT
2 FVU M 37 28 6395 E WT WT C1515T C1515T WT
3 FVU F 35 21 6679 E NA WT C1515T C1515T NA
4 FVU F 18 46 6118 E WT WT C1515T C1515T WT
5 FVU F 42 20 6434 E WT WT C1515T NA WT
6 FVU M 28 19 6850 C1515T
7 FVU F 20 39 7137 E WT WT C1515T C1515T WT
8 FVU F 23 42 7264 E WT WT C1515T C1515T WT
9 FVU M 26 20 7337 E WT WT C1515T C1515T WT
10 FVU F 24 25 6827 E NA WT C1515T C1515T NA
11 FVU M 27 26 7318 E WT WT C1515T NA WT
12 FVU M 26 26 7250 E WT WT C1515T C1515T NA
13 FVU M 37 28 7221 E C1515T
14 FVU F 18 26 7163 E C1515T
15 FVU F 21 27 6991 E C1515T
16 FVU F 20 66 * 6948 G WT
17 Pharyngealswab F 24 21 7506 E C1515T
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Table 2. Cont.
Specimen Number,
GenBank Accession
Number
Specimen
Type
Patient’s AC2
RLU
(×1000)
ACT
RLU
(×1000)
Genotype
MOMP
Sequence of Amplicons
Sex Age U23, 23SIG V1 V2 V3 V4
18 FVU M 29 23 7102 E C1515T
19 FVU M 24 24 7324 E C1515T
20 FVU F 24 24 7066 E C1515T
21 FVU F 29 25 7083 E C1515T
22 FVU F 22 25 7063 E C1515T
23 Cervicalswab F 26 28 7135 E C1515T
24 FVU M 21 17 6882 E C1515T
25 Rectal swab F 18 15 6920 NA C1515T
26 Cervicalswab F 28 18 7008 E C1515T
27 Pharyngealswab M 30 23 6485 E C1515T
28 FVU F 34 22 7121 E C1515T
29 FVU F 38 28 7142 E C1515T
30 FVU M 50 24 6803 E C1515T
31 FVU F 24 20 6748 E C1515T
32 FVU F 26 32 6882 E C1515T
33 FVU M 33 25 6848 E C1515T
34 FVU M 32 25 7087 E C1515T
35 FVU M 23 33 6870 E C1515T
36 FVU F 33 18 6899 E C1515T
37 FVU F 29 23 6944 E C1515T
38 FVU M 38 29 6826 E C1515T
39 FVU M 34 27 6673 E C1515T
40 FVU M 29 26 6806 E C1515T
*—equivocal; NA—not available (sequence not readable); WT—wild type; C1515T—mutation in position 1515.
Figure 5. The single mutation C1515T in 23S rRNA gene of Chlamydia trachomatis. Alignment of
sequences of samples 1–5 (Table 2), an Aptima Combo 2 positive sample and a reference strain, and
chromatograms of control strain genotype E and sample 1 showing the mutation.
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4. Discussion
The SNP C1515T in the 23S rRNA gene was the only difference initially observed between 10 AC2
negative or equivocal/ACT positive and AC2 positive samples [13]. Although the samples containing
this SNP (FI-nvCT samples) had RLUs slightly above the background level (RLU 15–46), they were
initially interpreted negative for C. trachomatis by the Panther instruments. In the present study, the
presence of the FI-nvCT was further confirmed in an additional 29 AC2/ACT discordant samples. The
ACT has higher analytical sensitivity than AC2, which may explain why AC2 negative/equivocal
but ACT positive test results are not necessarily related to the FI-nvCT (see sample No. 16 in
Table 2). However, 17 of the 20 AC2 negative/ACT positive samples with RLUs 15-24 were positive for
C. trachomatis by a multiplex PCR (Allplex™ CT/NG/MG/TV, Seegene) test in HUSLAB. This implies
that the majority of our discordant results were not due to a low bacterial load. All FI-nvCT samples
that could be genotyped were C. trachomatis type E. As genotype E is the most common genotype in
Finland [11] and in most other countries globally [7], this observation neither confirms nor excludes
that the variant strain is of clonal origin. Whole genome sequencing of the FI-nvCT specimens will
disclose whether there are additional changes in the bacterial genome. Notably, the Swedish nvCT
strain was also of genotype E, and, in addition to the 377 bp deletion, it had a 44 bp duplication in the
plasmid DNA [19].
All three methodological steps in the AC2 test could theoretically be affected by a mutation:
target capture-based sample preparation, transcription mediated amplification of rRNA through DNA
intermediates, and detection of amplified RNA using hybridization protection assay (HPA). As soon as
the initial false-negative AC2 CT specimens were detected [13], the manufacturer was informed and
after internal investigation, the manufacturer disclosed that 23S rRNA gene C1515T SNP we discovered
yields a significantly suppressed C. trachomatis detection probe-signal [20]. In HPA, chemiluminescent
acridium ester-labeled probes bind to complementary RNA amplicons. During detection, alkaline
hydrolysis destroys chemiluminescence of unhybridized probes, whereas in hybridized probes, the
acridium ester label is sterically protected from hydrolysis. HPA has earlier been shown to detect SNPs
in synthetic DNA and RNA oligos, and SNPs were shown to reduce the signal to ≤1% of the signal
obtained with a 100% matched target sequence [21]. This is in accordance with our observation: samples
with the FI-nvCT resulted in very significantly reduced signal in the AC2 and were consequently
interpreted as negative. To streamline clinical sample testing with Aptima, Hologic is developing
a new assay that specifically targets the FI-nvCT [20,22]. Recently, initial evaluation revealed that
two cases of FI-nvCT have been identified in Sweden [18]. As ECDC has been notified and ECDC
has informed public health officials in Europe, we expect more information on the epidemiology of
FI-nvCT to accumulate.
At present, it remains unknown when the FI-nvCT appeared in Finland. The earliest available
specimen that contained the FI-nvCT was sampled in June 2018 in Turku. The patient’s FVU sample had
been AC2 negative for C. trachomatis, and a week later a new sample was referred to be tested with the
Anyplex II STI-5 multiplex PCR and stored. Anyplex II STI-5 targeting several genital mycoplasmas and
Trichomonas vaginalis but not C. trachomatis, was originally introduced in Turku in 2014 as a secondary
STI-test mainly to detect Mycoplasma genitalium in symptomatic patients negative for C. trachomatis and
N. gonorrhoeae. Had that panel originally contained C. trachomatis we might have caught the variant 8
months earlier, showing that the use of a backup NAAT may be an effective means to catch possible
diagnostic escape mutants when primary testing remains negative in symptomatic patients. Now, the
first FI-nvCT cases in February 2019 were discovered by chance and without testing for C. trachomatis
with a NAAT using a different target (Allplex STI Essential) they would have remained unnoticed.
Retrospectively analyzed RLUs of specimens from 2016–2018 showed that the proportion of AC2
negative specimens with RLUs 20–84 started to increase in 2017. Additionally, the analysis of nearly
434,000 AC2 negative samples tested in HUSLAB indicates that the proportion of samples with RLUs
10–19 started to increase already in 2014. There are a number of explanations for such a phenomenon,
including those related to slight variations in the reagent lots and elevated RLUs associated with
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incompletely dissolved reagents, as well as technical issues of Panther instruments possibly causing
a gradual shift in the RLU background level. Another explanation is the appearance of FI-nvCT in
the Helsinki metropolitan area in late 2014, and gradually spreading thereafter. Interestingly, among
patients confirmed to carry the FI-nvCT, one (No. 12) had given a sample with RLU 23 already in 2015.
Further epidemiological and molecular investigations are needed to establish the time of appearance
of the FI-nvCT in Finland.
It is noteworthy that, contrary to the episode in Sweden with the appearance of the Swedish nvCT,
no decrease in the number of mandatorily notified C. trachomatis cases was observed nationally in
Finland in 2010–2019. Locally, however, the incidence of C. trachomatis cases showed a decreasing
tendency in the hospital district of Southwest Finland (Turku) in 2018, where AC2 is used (the change
did not reach statistical significance). Most C. trachomatis cases in Finland are reported from the hospital
district of Helsinki and Uusimaa, and although a majority of samples are being diagnosed by AC2,
the incidence has been on the increase since 2015 suggesting that the clearly rising incidence of C.
trachomatis infections is masking the presence of FI-nvCT in that area. In HUSLAB, Tyks and UML, the
proportion of FI-nvCT is estimated as 6–9% of C. trachomatis cases.
The C. trachomatis rRNA operon contains the genes encoding the chlamydial 5S, 16S, and 23S
rRNA and the C1515T SNP found here is in the region coding for domain II of C. trachomatis 23S rRNA.
There are two copies of the rRNA operon in the C. trachomatis genome [23] and the 23S rRNA gene in
the two operons has been considered to be identical. Whether the observed mutation is present in one
copy or both copies of the operon is not known yet. However, according to the Sanger sequencing
chromatograms there are no mixed sequences which indicate that the C1551T is likely in both copies
(also supported by our preliminary PCR data). Nevertheless, whole genome sequencing, which is in
progress, will be needed to provide clearer evidence regarding this issue. 16S rRNA and 23S rRNA are
structural components of ribosomes and their function as well as structure is well preserved. SNPs in
the 23S rRNA peptidyltransferase region within domain V are associated with resistance to macrolides
in other bacteria, and domain II can interact with domain V [24]. Based on the position of the C1515T
mutation in 23S rRNA, most likely it does not affect susceptibility to macrolides, however, it cannot be
completely excluded. It remains to be studied, whether the FI-nvCT has altered biological properties
such as altered transmissibility, pathogenicity, or general fitness.
Variants of microbes evolve, and their emergence can create detection problems with NAATs [8].
Even SNPs can severely compromise nucleic acid amplification and/or detection when unfavorably
positioned, as was observed in this study. When evaluating and implementing diagnostic tests,
known variants can be taken into consideration while an emerging diagnostic escape variant is more
problematic for clinical laboratories, since established quality assessment programs cover only known
strains of microbes. NAATs with dual targets or frequent testing of random samples of negatives with
another assay having another target would be helpful. In addition, careful and preferably automated
monitoring of long-term trends (epidemiology, positivity rate, and assay signal values) is an essential
component of quality confirmation in diagnostics.
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